Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company, Orchestra BioMed uses current reports on Form 8-K and other filings to describe material agreements, financings, collaborations and governance matters related to its biomedical innovation business.
In these filings, investors can find detailed information about the company’s strategic and financial arrangements that support its flagship programs, Atrioventricular Interval Modulation (AVIM) Therapy and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB). Recent Form 8-K reports describe revenue participation agreements with Ligand Pharmaceuticals tied to future revenues from AVIM Therapy and Virtue SAB, a secured subordinated convertible loan agreement with Medtronic that can convert into a revenue share, and a termination and right of first refusal agreement with Terumo related to Virtue SAB for coronary artery disease.
Filings also cover underwritten public offerings of common stock and pre-funded warrants, private placements with institutional partners, preferred stock issuances, and stock purchase agreements that provide capital for pivotal clinical trials such as the BACKBEAT global study and the Virtue Trial. Additional disclosures include investor presentations furnished under Regulation FD, conference call transcripts, and annual meeting voting results.
On Stock Titan, these OBIO filings are complemented by AI-powered summaries that highlight key terms, counterparties and financial implications, helping readers quickly understand complex documents such as Form 8-Ks, registration statements and related exhibits. Users can review how Orchestra BioMed structures revenue interests, rights of first refusal, convertible instruments and collaboration amendments, and can monitor ongoing reporting about its status as an emerging growth company and its relationships with partners like Medtronic, Terumo and Ligand.
On 08/04/2025, RTW Investments, LP—together with Managing Partner Dr. Roderick Wong—filed a Form 4 disclosing the purchase of 3,636,363 pre-funded warrants in Orchestra BioMed Holdings (OBIO). The warrants were acquired at $2.7499 per warrant (Transaction Code “P”) and carry a nominal exercise price of $0.0001 per share. Each warrant is immediately exercisable into one common share, but exercise is limited so total beneficial ownership does not exceed 9.99 % of OBIO’s outstanding stock.
The filing confirms RTW and Dr. Wong as >10 % shareholders and directors. Post-transaction, they hold 3.64 million derivative securities that, if fully exercised, could add an equivalent number of common shares to OBIO’s float, creating potential dilution. The warrants have no expiration date, giving the insiders flexibility on timing.
Perceptive Advisors LLC and affiliated entities, already a >10 % shareholder of Orchestra BioMed Holdings (OBIO), filed Form 4 disclosing additional purchases on 1 Aug 2025.
- Acquired 700,000 common shares at $2.75 per share through the issuer’s registered public offering (transaction code “P”).
- Acquired 1,500,000 pre-funded warrants (exercise price $0.0001; purchase price $2.7499) that are immediately exercisable, subject to a beneficial-ownership cap.
- Following the transactions, indirect beneficial ownership stands at 5,292,556 common shares and 1,500,000 warrants.
- Filers listed are Perceptive Advisors LLC (investment manager), Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman (managing member). No dispositions were reported.
The filing signals continued capital commitment by a significant insider during the public offering.
Orchestra BioMed Holdings (OBIO) – Form 4 insider activity
On 08/04/2025, Chief Executive Officer & Chairperson David P. Hochman purchased 20,000 common shares in the company’s underwritten public offering at $2.75 per share, investing $55,000. The shares were bought indirectly through the DPH 2008 Trust, raising that trust’s position to 349,331 shares.
Following the acquisition, Hochman’s total beneficial ownership stands at 903,931 shares, consisting of 545,460 shares held directly and 358,471 shares held through five family trusts (DPH 2008, Solomon Ascher 2019, Hannah 2019, Judah Herman 2019, NSH 2008). No shares were sold and no derivative securities were reported in the filing.
The transaction increases the CEO’s economic exposure and signals participation in the recent capital raise, but the filing contains no financial results, guidance, or other operational disclosures.
Orchestra BioMed (OBIO) filed an 8-K announcing a $40 m underwritten equity offering and a concurrent $16.2 m private placement.
The public deal comprises 9.4 m common shares priced at $2.75 and 5.1 m pre-funded warrants priced at $2.7499; underwriters (Piper Sandler, TD Securities) hold a 30-day option for 2.18 m additional shares. Pre-funded warrants carry a $0.0001 exercise price and a 9.99 % beneficial-ownership cap, adjustable to 19.99 % on 61-days’ notice.
Immediately after the offering closed on 4 Aug 2025, the company sold 5.9 m shares to Ligand and a Medtronic affiliate in a PIPE, and issued Ligand a warrant for up to 2 m shares at $3.67. Aggregate gross proceeds reach roughly $56 m before fees.
OBIO plans to deploy the capital to advance its atrioventricular interval modulation therapy (BACKBEAT study) and Virtue Sirolimus AngioInfusion Balloon programs, and for general corporate purposes. The filing also includes customary indemnities, legal opinions and forward-looking-statement disclaimers.
Orchestra BioMed Holdings (OBIO) director Chris Cleary received new equity compensation grants on June 24, 2025. The awards consist of:
- 12,422 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 22,577 shares
- 36,797 Stock Options with an exercise price of $3.22 per share, expiring June 24, 2035
Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. This Form 4 filing was submitted by Andrew Taylor as attorney-in-fact on June 26, 2025, reflecting standard director compensation arrangements.
Orchestra BioMed Holdings (OBIO) director John Prosper Mack received two equity awards on June 24, 2025:
- 12,422 Restricted Stock Units (RSUs) with a $0 exercise price
- 36,797 Stock Options with an exercise price of $3.22 per share and expiration date of June 24, 2035
Both awards vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. Following these transactions, Mack directly owns 25,286 shares of common stock and 36,797 stock options. This compensation structure aligns the director's interests with shareholders through both full-value shares and appreciation-only options.
Orchestra BioMed Holdings (OBIO) reported insider trading activity through a Form 4 filing for director Pamela Ann Connealy. On June 24, 2025, Connealy received two equity awards:
- 12,422 Restricted Stock Units (RSUs) with zero exercise price, bringing her total direct ownership to 33,711 shares
- 36,797 Stock Options with an exercise price of $3.22, expiring June 24, 2035
Both awards vest in a single installment at the earlier of: (1) one-year anniversary of the grant date, or (2) the 2026 Annual Meeting of Stockholders, subject to continuous service. The transaction was executed pursuant to the company's director compensation program, with the filing submitted by Andrew Taylor as attorney-in-fact on June 26, 2025.